Antibiotic cover of transurethral maneuvers with ciprofloxacin and susceptibility behavior of pathogens in patients with neurogenic bladder

Van Poppel H, Willemen P, Wegge M, Kraseman P, Chysky V, Baert L

Urologia internationalis, 1990

Abstract

The resistance-inducing capacity of ciprofloxacin is still controversial. In order to assess the changes in susceptibility behavior, ciprofloxacin was given as antibiotic cover for transurethral maneuvers in multiple sclerosis (MS) patients with urinary tract infection prone to recurrence after treatment. The aim was to compare the susceptibility pattern before and after treatment in a double-blind study using two different dose regimens. Sixty-one patients were randomly separated in two groups who received 100 and 500 mg ciprofloxacin orally, twice a day for 4 days. Bacterial cultures were performed before and at the fourth day of treatment as well as at 6 days and 4 weeks after the end of treatment. Altered susceptibility behavior, defined as an elevation of the primary minimum inhibitory concentration by at least two dilution steps, was only found in three causative organisms out of 86, demonstrating the low resistance-inducing capacity of ciprofloxacin. There was no significant dosage-related difference.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

• DOI
• PubMed
• Publisher page

Related studies

• Horizontal gene transfer in the human gastrointestinal tract: potential spread of antibiotic resistance genes Infection and Drug Resistance, 2014
• Mutation supply and relative fitness shape the genotypes of ciprofloxacin-resistant Escherichia coli Molecular Biology and Evolution, 2017
• Genomic Survey of E. coli From the Bladders of Women With and Without Lower Urinary Tract Symptoms Frontiers in Microbiology, 2020
• Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017–18 Journal of Antimicrobial Chemotherapy, 2019
• Fitness cost constrains the spectrum of marR mutations in ciprofloxacin-resistant Escherichia coli Journal of Antimicrobial Chemotherapy, 2017
• Emerging evidence-based innovative approaches to control catheter-associated urinary tract infection: a review Frontiers in Cellular and Infection Microbiology, 2023

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free